THAT WHICH IS CLAIMED IS:

1. A compound according to Formula I:



(I)

wherein:

X_1 and X_3 are each independently selected from the group consisting of O, S and NR_9, wherein R_9 is H or alkyl;

X_2 and X_4 are each independently CH or N;

A is selected from the group consisting of H, alkyl, aryl,



and

;

R_1, R_2, R_3, R_4 and R_5 are each independently selected from the group consisting of H, alkyl, alkoxy, halide, alkylhalide, amidine, nitro and amino groups;

R_6 is H, alkyl or aryl; and

R_7 and R_8 are each independently selected from the group consisting of H and alkyl.

2. The compound according to Claim 1, wherein:

X_1 is O;

X_2 is C;

X_3 is NH

X_4 is N and

R_2, R_3 and R_4 are each H.

3. The compound according to Claim 1, wherein A is



and R_6 is alkyl.

4. The compound according to Claim 1, wherein A is



and R_7 and R_8 are each H.

5. The compound according to Claim 1, wherein R_1 is an amino group.

6. The compound according to Claim 1, wherein R_1 is a nitro group.

7. The compound according to Claim 1, wherein the compound is represented by the formula:



8. The compound according to Claim 1, wherein the compound is represented by the formula:



9. The compound according to Claim 1, wherein the compound is represented by the formula:



10. The compound according to Claim 1, wherein the compound is represented by the formula:



11. A pharmaceutical composition comprising a compound of Claim 1, in a pharmaceutically acceptable carrier.

12. The pharmaceutical composition according to Claim 11, wherein the composition is formulated for intravenous administration.

13. The pharmaceutical composition according to Claim 11, wherein the composition is formulated for oral administration.

14. A compound according to Formula II:



(II)

wherein:

X_1 and X_3 are each independently selected from the group consisting of O, S and NR_9, wherein R_9 is H or alkyl;

X_2 and X_4 are each independently CH or N;

A is selected from the group consisting of H, alkyl, aryl,



and

;

R_1, R_2, R_3, R_4 and R_5 are each independently selected from the group consisting of H, alkyl, alkoxy, halide, alkylhalide, amidine, nitro and amino groups;

R_6 is H, alkyl or aryl; and

R_7 and R_8 are each independently selected from the group consisting of H and alkyl.

15. A pharmaceutical composition comprising a compound of Claim 14, in a pharmaceutically acceptable carrier.

16. The pharmaceutical composition according to Claim 15, wherein the composition is formulated for intravenous administration.

17. The pharmaceutical composition according to Claim 15, wherein the composition is formulated for oral administration.

18. A compound according to Formula III:



wherein:

X_1 and X_3 are each independently selected from the group consisting of O, S and NR_9, wherein R_9 is H or alkyl;

X_2 and X_4 are each independently CH or N;

A is selected from the group consisting of H, alkyl, aryl,



R_1, R_2, R_3, R_4 and R_5 are each independently selected from the group consisting of H, alkyl, alkoxy, halo, amidine, nitro and amino groups;

R_6 is H, alkyl or aryl; and

R_7 and R_8 are each independently selected from the group consisting of H and alkyl.

19. A pharmaceutical composition comprising a compound of Claim 18, in a pharmaceutically acceptable carrier.

20. The pharmaceutical composition according to Claim 19, wherein the composition is formulated for intravenous administration.

21. The pharmaceutical composition according to Claim 19, wherein the composition is formulated for oral administration.

22. A compound according to Formula IV:



(IV)

wherein:

X_1 and X_3 are each independently selected from the group consisting of O, S and NR_9, wherein R_9 is H or alkyl;

X_2 and X_4 are each independently CH or N;

A is selected from the group consisting of H, alkyl, aryl,



R_1, R_2, R_3, R_4 and R_5 are each independently selected from the group consisting of H, alkyl, alkoxy, halide, alkylhalide, amidine, nitro and amino groups;

R_6 is H, alkyl or aryl; and

R_7 and R_8 are each independently selected from the group consisting of H and alkyl.

23. A pharmaceutical composition comprising a compound of Claim 22, in a pharmaceutically acceptable carrier.

24. The pharmaceutical composition according to Claim 23, wherein the composition is formulated for intravenous administration.

25. The pharmaceutical composition according to Claim 23, wherein the composition is formulated for oral administration.

26. A compound according to Formula V:



(V)

wherein:

X_1 is independently selected from the group consisting of O, S and NR_9, wherein R_9 is H or alkyl;

X_2 is CH or N;

A is selected from the group consisting of H, alkyl, aryl,



R_1, R_2, R_3, R_4 and R_5 are each independently selected from the group consisting of H, alkyl, alkoxy, halide, alkylhalide, amidine, nitro and amino groups;

R_6 is H, alkyl or aryl; and

R_7 and R_8 are each independently selected from the group consisting of H and alkyl.

27. A compound according to Claim 26, wherein:

X_1 is O;

X_2 is C; and

R_2 and R_3 are each H.

28. A compound according to Claim 26, wherein A is



and R_7 and R_8 are each H.

29. A compound according to Claim 26, wherein R_1 is alkoxy.

30. A compound according to Claim 26 , wherein the compound is represented by the formula:



31. A pharmaceutical composition comprising a compound of Claim 30, in a pharmaceutically acceptable carrier.

32. The pharmaceutical composition according to Claim 31, wherein the composition is formulated for intravenous administration.

33. The pharmaceutical composition according to Claim 31, wherein the composition is formulated for oral administration.

34. A compound according to Formula VI:



(VI)

wherein:

X_1 is selected from the group consisting of O, S and NR_9, wherein R_9 is H or alkyl;

X_2 is CH or N;

A is selected from the group consisting of H, alkyl, aryl,



R_1, R_2, R_3, R_4 and R_5 are each independently selected from the group consisting of H, alkyl, alkoxy, halide, alkylhalide, amidine, nitro and amino groups;
R_6 is H, alkyl or aryl; and
R_7 and R_8 are each independently selected from the group consisting of H and alkyl.

35. The compound according to Claim 34, wherein X_1 is O and X_2 is C.

36. The compound according to Claim 34, wherein X_1 is NH and X_2 is C.

37. The compound according to Claim 34, wherein X_1 is S and X_2 is C.

38. The compound according to Claim 34, wherein X_1 is S and X_2 is N.

39. The compound according to Claim 34, wherein the compound is represented by the formula



40. The compound according to Claim 34, wherein the compound is represented by the formula



41. The compound according to Claim 34, wherein the compound is represented by the formula



42. The compound according to Claim 34, wherein the compound is represented by the formula



43. The compound according to Claim 34, wherein the compound is represented by the formula



44. The compound according to Claim 34, wherein the compound is represented by the formula



45. The compound according to Claim 34, wherein the compound is represented by the formula



46. The compound according to Claim 34, wherein the compound is represented by the formula



47. The compound according to Claim 34, wherein the compound is represented by the formula



48. The compound according to Claim 34, wherein the compound is represented by the formula



49. The compound according to Claim 34, wherein the compound is represented by the formula



50. A pharmaceutical composition comprising a compound of Claim 34, in a pharmaceutically acceptable carrier.

51. The pharmaceutical composition according to Claim 50, wherein the composition is formulated for intravenous administration.

52. The pharmaceutical composition according to Claim 50, wherein the composition is formulated for oral administration.

53. A method of treating bovine viral diarrhea virus (BVDV) infection in a subject in need of such treatment, comprising administering to the subject a compound selected from the group consisting of Formula I and Formula II:



(I)



(II)

wherein:

X_1 and X_3 are each independently selected from the group consisting of O, S and NR_9, wherein R_9 is H or alkyl;

X_2 and X_4 are each independently CH or N;

A is selected from the group consisting of H, alkyl, aryl,



R_1, R_2, R_3, R_4 and R_5 are each independently selected from the group consisting of H, alkyl, alkoxy, halide, alkylhalide, amidine, nitro and amino groups;

R_6 is H, alkyl or aryl; and

R_7 and R_8 are each independently selected from the group consisting of H and alkyl;

or a pharmaceutically acceptable salt thereof, in an amount sufficient to treat the bovine viral diarrhea virus (BVDV) infection.

54. The method according to Claim 53, wherein the compound is a compound of Formula I.

55. The method according to Claim 53, wherein the compound is represented by the formula:



56. The method according to Claim 53, wherein the subject is a cow.

57. The method according to Claim 53, wherein the subject is an embryo.

58. The method according to Claim 53, wherein the compound is administered intravenously.

59. The method according to Claim 53, wherein the compound is administered orally.

60. A method of treating bovine viral diarrhea virus (BVDV) infection in a subject in need of such treatment, comprising administering to the subject a compound selected from the group consisting of Formula III and Formula IV:



(III)



(IV)

wherein:

X_1 and X_3 are each independently selected from the group consisting of O, S and NR_9, wherein R_9 is H or alkyl;

X_2 and X_4 are each independently CH or N;

A is selected from the group consisting of H, alkyl, aryl,



R_1, R_2, R_3, R_4 and R_5 are each independently selected from the group consisting of H, alkyl, alkoxy, halide, alkylhalide, amidine, nitro and amino groups;

R_6 is H, alkyl or aryl; and

R_7 and R_8 are each independently selected from the group consisting of H and alkyl;

or a pharmaceutically acceptable salt thereof, in an amount sufficient to treat the bovine viral diarrhea virus (BVDV) infection.

61. A method of treating bovine viral diarrhea virus (BVDV) infection in a subject in need of such treatment, comprising administering to the subject a compound selected from the group consisting of Formula V and Formula VI:





wherein:

X_1 and X_3 are each independently selected from the group consisting of O, S and NR_9, wherein R_9 is H or alkyl;

X_2 and X_4 are each independently CH or N;

A is selected from the group consisting of H, alkyl, aryl,



R_1, R_2, R_3, R_4 and R_5 are each independently selected from the group consisting of H, alkyl, alkoxy, halide, alkylhalide, amidine, nitro and amino groups;

R_6 is H, alkyl or aryl; and

R_7 and R_8 are each independently selected from the group consisting of H and alkyl;

or a pharmaceutically acceptable salt thereof, in an amount sufficient to treat the bovine viral diarrhea virus (BVDV) infection.

62. The method according to Claim 61, wherein the subject is a cow.

63. The method according to Claim 61, wherein the subject is an embryo.

64. The method according to Claim 61, wherein the compound is administered intravenously.

65. The method according to Claim 61, wherein the compound is administered orally.

66. The method according to Claim 61, wherein the compound is represented by the formula:



67. The method according to Claim 61, wherein the compound is represented by the formula



68. The method according to Claim 61, wherein the compound is represented by the formula



69. The method according to Claim 61, wherein the compound is represented by the formula



70. The method according to Claim 61, wherein the compound is represented by the formula



71. The method according to Claim 61, wherein the compound is represented by the formula



72. The method according to Claim 61, wherein the compound is represented by the formula



73. The method according to Claim 61, wherein the compound is represented by the formula



74. The method according to Claim 61, wherein the compound is represented by the formula



75. The method according to Claim 61, wherein the compound is represented by the formula



76. The method according to Claim 61, wherein the compound is represented by the formula



77. The method according to Claim 61, wherein the compound is represented by the formula



78. A method of treating hepatitis C infection in a subject in need of such treatment, comprising administering to the subject a compound selected from the group consisting of Formula I and Formula II:



(I)



(II)

wherein:

X_1 and X_3 are each independently selected from the group consisting of O, S and NR_9, wherein R_9 is H or alkyl;

X_2 and X_4 are each independently CH or N;

A is selected from the group consisting of H, alkyl, aryl,



R_1, R_2, R_3, R_4 and R_5 are each independently selected from the group consisting of H, alkyl, alkoxy, halide, alkylhalide, amidine, nitro and amino groups;

R_6 is H, alkyl or aryl; and

R_7 and R_8 are each independently selected from the group consisting of H and alkyl;

or a pharmaceutically acceptable salt thereof, in an amount sufficient to treat the hepatitis C infection.

79. The method according to Claim 78, wherein the compound is a compound of Formula I.

80. The method according to Claim 78, wherein the compound is represented by the formula:



81. The method according to Claim 78, wherein the subject is a human.

82. The method according to Claim 78, wherein the compound is administered intravenously.

83. The method according to Claim 78, wherein the compound is administered orally.

84. A method of treating hepatitis C infection in a subject in need of such treatment, comprising administering to the subject a compound selected from the group consisting of Formula III and Formula IV:



(III)



(IV)

wherein:

X_1 and X_3 are each independently selected from the group consisting of O, S and NR_9, wherein R_9 is H or alkyl;

X_2 and X_4 are each independently CH or N;

A is selected from the group consisting of H, alkyl, aryl,



R_1, R_2, R_3, R_4 and R_5 are each independently selected from the group consisting of H, alkyl, alkoxy, halide, alkylhalide, amidine, nitro and amino groups;

R_6 is H, alkyl or aryl; and

R_7 and R_8 are each independently selected from the group consisting of H and alkyl;

or a pharmaceutically acceptable salt thereof, in an amount sufficient to treat the hepatitis C infection.

85. A method of treating hepatitis C infection in a subject in need of such treatment, comprising administering to the subject a compound selected from the group consisting of Formula V and Formula VI:



wherein:

X_1 and X_3 are each independently selected from the group consisting of O, S and NR_9, wherein R_9 is H or alkyl;

X_2 and X_4 are each independently CH or N;

A is selected from the group consisting of H, alkyl, aryl,



R_1, R_2, R_3, R_4 and R_5 are each independently selected from the group consisting of H, alkyl, alkoxy, halide, alkylhalide, amidine, nitro and amino groups;

R_6 is H, alkyl or aryl; and

R_7 and R_8 are each independently selected from the group consisting of H and alkyl; or a pharmaceutically acceptable salt thereof, in an amount sufficient to treat the hepatitis C infection.

86. The method according to Claim 85, wherein the subject is a human.

87. The method according to Claim 85, wherein the compound is administered intravenously.

88. The method according to Claim 85, wherein the compound is administered orally.

89. The method according to Claim 85, wherein the compound is represented by the formula:



90. The method according to Claim 85, wherein the compound is represented by the formula



91. The method according to Claim 85, wherein the compound is represented by the formula



92. The method according to Claim 85, wherein the compound is represented by the formula



93. The method according to Claim 85, wherein the compound is represented by the formula



94. The method according to Claim 85, wherein the compound is represented by the formula



95. The method according to Claim 85, wherein the compound is represented by the formula



96. The method according to Claim 85, wherein the compound is represented by the formula



97. The method according to Claim 85, wherein the compound is represented by the formula



98. The method according to Claim 85, wherein the compound is represented by the formula



99. The method according to Claim 85, wherein the compound is represented by the formula



100. The method according to Claim 85, wherein the compound is represented by the formula



101. A method of treating a member of the *Flaviviridae* family of viruses in a subject in need of such treatment, comprising administering to the subject a compound selected from the group consisting of Formula I and Formula II:



(I)



(II)

wherein:

X_1 and X_3 are each independently selected from the group consisting of O, S and NR_9, wherein R_9 is H or alkyl;

X_2 and X_4 are each independently CH or N;

A is selected from the group consisting of H, alkyl, aryl,



R_1, R_2, R_3, R_4 and R_5 are each independently selected from the group consisting of H, alkyl, alkoxy, halide, alkylhalide, amidine, nitro and amino groups;

R_6 is H, alkyl or aryl; and

R_7 and R_8 are each independently selected from the group consisting of H and alkyl; or a pharmaceutically acceptable salt thereof, in an amount sufficient to treat the bovine viral diarrhea virus (BVDV) infection.

102. The method according to Claim 101, wherein the compound is a compound of Formula II.

103. The method according to Claim 101, wherein the compound is represented by the formula:



104. The method according to Claim 101, wherein the compound is represented by the formula:



105. The method according to Claim 101, wherein the compound is administered intravenously.

106. The method according to Claim 101, wherein the compound is administered orally.